In the primary analysis of a phase 3 study, ruxolitinib reduced spleen length and symptoms in patients with myelofibrosis, according to results published in British Journal of Haemotology.
In the primary analysis of a phase 3 study, ruxolitinib, a Janus kinase (JAK) 1/JAK2 inhibitor, reduced spleen length and symptoms in patients with myelofibrosis (MF), according to results published in British Journal of Haemotology.
The JAK Inhibitor Ruxolitinib in Myelofibrosis Patients (JUMP) study was a global, single-arm, open-label, phase 3b, expanded-access trial. With 2233 patients, it is the largest and most expansive trial in patients with MF treated with ruxolitinib. In the study results, the authors presented the safety and efficacy results for all patients and a subgroup analysis (n = 138) of patients with low platelet counts (<100 x 109/1) at baseline.
The primary end point of JUMP was safety and tolerability or ruxolitinib by frequency, duration, and severity of adverse events (AEs).
The majority of patients were either intermediate-1 (37.4%) or intermediate-2 (33.8%) risk based on the dynamic International Prognostic Scoring System. The patients with low platelet counts at baseline had “disease characteristics that were consistent with more advanced disease,” based on hemoglobin levels and mean palpable spleen length, the authors noted.
More than half (57.5%) of all patients completed their treatment per protocol and the primary reason for discontinuation was AEs (18.1%), followed by disease progression (9.1%), and death (4.5%). The median exposure to ruxolitinib was 12.4 months; 51% of patients had more than 1 year of exposure and 30% and 13% of patients had greater than 2 and 3 years of exposure, respectively. However, patients in the low-platelet cohort had a lower median exposure (8.3 months).
The most common hematologic AEs were anemia (59.5%) and thrombocytopenia (53.5%). However, these AEs were manageable, since only 2.0% of patients with anemia and 3.4% of patients with thrombocytopenia discontinued treatment due to these AEs. Serious AEs included pneumonia (5.5%), anemia (4.2%), pyrexia (3.5%), cardiac failure (1.9%), dyspnea (1.6%), respiratory failure (1.2%), thrombocytopenia (1.1%), and urinary tract infection (1.0%).
More than half (56.5%) of patients with splenomegaly achieved a 50% or greater reduction from baseline to week 24 in palpable spleen length. By week 48, 61.4% had achieved a response and by week 96, 66.5% had achieved a response. Approximately a quarter (24.7%) of patients had a resolution of splenomegaly.
Overall survival probability was estimated at 94% (95% CI, 92%-95%) at 48 weeks and 87% (95% CI, 85%-89%) at 96 weeks. In addition, there were 205 deaths (9.2%) either on treatment or reported up to 28 days after the end of treatment.
The authors concluded that the findings from JUMP confirm the findings from the phase 3 COMFORT studies, while providing additional efficacy and safety evidence. They also noted that continued analysis is needed to determine the long-term efficacy of ruxolitinib.
“However, it is important to interpret our findings with caution given the limitations associated with a single-arm study and the small number of patients in the [intermediate-1]–risk and low-platelet cohorts; additionally, because comparisons of patient subgroups were conducted as a post-hoc analysis, no statistical testing was performed,” they explained.
Reference
Al-Ali HK, Greisshammer M, Foltz L, et al. Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts. Br J Haematol. 2020;189(5):888-903. doi:10.1111/bjh.16462
What We’re Reading: Abortion Privacy Rules; Alzheimer Drug Hurdles; Nursing Home Staffing Overhaul
April 23rd 2024New health privacy rules aim to protect patients and providers in an evolving abortion landscape; some physicians express concerns about efficacy, risks, and entrenched beliefs in treating Alzheimer disease; CMS addresses longstanding staffing deficits in nursing homes.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Survey Results Reveal Potential Factors Slowing the Decline in Cardiovascular Mortality Rate
April 23rd 2024Research indicated that worsened glycemic, blood pressure, and obesity control, as well as increased alcohol consumption, leveled lipid control, and persistent socioeconomic disparities may have contributed to the decelerated cardiovascular mortality decline in recent years.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen